Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

STABILITY will assess whether direct inhibition of Lp-PLA2 with darapladib added to the standard of care confers clinical benefit to patients with CHD.